Research Articles | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations Jun 2023 Advances in Therapy Paroxysmal Nocturnal Hemoglobinuria (PNH)
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML Jul 2020 Aging Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Calculator-free point-of-care prognostication in myelodysplastic syndromes. Jan 2019 Am J Hematol Myelodysplastic Syndromes (MDS)
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry Jan 2019 Am J Hematol Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH)
How I Diagnose Low-Grade Myelodysplastic Syndromes May 2020 American Journal of clinical Pathology Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management Aug 2020 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" Jan 2021 American Journal of Hematology Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN)
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes Nov 2019 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study Jul 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes Jan 2021 American Journal of Hematology Myelodysplastic Syndromes (MDS)